estradiol transdermal system

estradiol transdermal system,

n brand names: Esbrand, Climera;
drug class: estrogen;
action: increases synthesis of deoxyribonucleic acid, ribonucleic acid, and selected proteins; decreases release of gonadotropin-releasing hormone; inhibits ovulation and helps maintain bone structure;
uses: menopause, prostatic cancer, abnormal uterine bleeding, hypogonadism, ovariectomy, osteoporosis.
References in periodicals archive ?
Estradiol transdermal system versus oral estrogen-only hormone therapy.
Pharmaceutical company Mylan (NasdaqGS:MYL) said on Tuesday that it has unveiled its Estradiol Transdermal System USP, 0.
The company said the Estradiol Transdermal System USP is the generic version of Novartis' Vivelle-DOT.
This is in contrast to Ortho Evra (norelgestromin/ethinyl estradiol transdermal system, Ortho-McNeil-Janssen Pharmaceuticals), the first-generation contraceptive patch that gained popularity upon release, but was found to deliver a dose of EE substantially higher than conventional oral contraceptives.
Beresford and colleagues compared VTE incidence for up to 90 days in 27,018 women who began taking oral estrogen only, and in 27,018 who began using a high-dose estradiol transdermal system (ETS) between January 2002 and October 2009.
M2 EQUITYBITES-April 17, 2014-Mylan unveils US FDA approved XULANE (Norelgestromin/Ethinyl Estradiol Transdermal System 150/35 mcg per day) for the prevention of pregnancy
M2 PHARMA-April 17, 2014-Mylan unveils US FDA approved XULANE (Norelgestromin/Ethinyl Estradiol Transdermal System 150/35 mcg per day) for the prevention of pregnancy
Beresford and colleagues compared VTE incidence for up to 90 days in 27,018 women who began taking oral estrogen only, and in 27,018 who began using an estradiol transdermal system (ETS) between January 2002 and October 2009.
Use of the norelgestromin ethinyl estradiol transdermal system (Ortho-Evra) on an 84-day cycle delayed the median time to first bleeding by 54 days among healthy, normally menstruating women, according to data collected by Dr.
Mylan was reportedly the first company to have filed a substantially complete abbreviated new drug application with a Paragraph IV certification with the US Food and Drug Administration for Estradiol Transdermal System USP, twice-weekly, which had recorded total US sales of USD240m for the 12 months ending 30 September 2011.
Mylan said in a statement it was the first company to have submitted an Abbreviated New Arug Application (ANDA) containing a Paragraph IV certification with the US Food and Drug Administration (FDA) for estradiol transdermal system USP, twice-weekly.
Food and Drug Administration to manufacture and market Estradiol Transdermal System 0.